A Phase 3 interventional study of Fluticasone propionate and Placebo in Allergic Rhinitis and Seasonal Allergic Rhinitis, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-03.
Sponsored by GlaxoSmithKline · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Seasonal.
Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 14 in phase 3, and was the 23rd registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 626 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 326 across the 28 interventional studies. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 28 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 31 finished, 10 (32%) have results posted.
Among the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 10 in phase 3, and was the 28th registered.
GlaxoSmithKline’s Rhinitis, Allergic, Seasonal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Rhinitis, Allergic, Seasonal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).
While the current FP approved indication for GSK marketed formulation is limited to the treatment of nasal symptoms, several large well-controlled studies in which FP maintained adequate control of nasal symptoms when administered in a dose of 200 micrograms (mcg) once-daily (QD) also suggested improvement in ocular symptoms. This study will employ a randomized, double-blind, parallel group, multi-center design that compares FP and placebo nasal sprays in subjects with seasonal allergic rhinitis (SAR) to assess the effectiveness on ocular symptoms associated with AR.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
This study's enrollment of 626 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with diagnosis of seasonal allergic rhinitis
Participants with allergic rhinitis symptom of at least moderate severity for randomization:
Exclusion Criteria:
Participants with nasal disorders like:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
Drug: Fluticasone propionate
Two sprays of placebo per nostril to be administered in morning.
Drug: Placebo
Nasal spray formulation (200 mcg/day)
Also known as: Flonase
Vehicle for Fluticasone propionate aqueous nasal spray
Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)
The Reflective Total Ocular Symptom Score (rTOSS) is the sum of 3 individual participant-assessed symptom scores (eye itching/burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. Subjects completed rTOSS in the evening (PM rTOSS; 12 hours post morning nasal spray use) and once in the morning (AM score: prior to nasal spray use). Daily (i.e. during one dosing interval) rTOSS is defined as the average of the PM rTOSS and the AM rTOSS of the next day prior to AM dosing. The mean change from baseline in (daily, AM, PM) TOSS was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in AM rTOSS
rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For AM rToss, subjects completed rTOSS in the morning (AM score: prior to nasal spray use). The mean change from baseline in AM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in PM rTOSS
rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For PM rTOSS, subjects completed rTOSS in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning
The AM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning
The PM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering
The AM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering
The PM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness
The AM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness
The PM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)
Instantaneous total ocular symptom scores (iTOSS) assessments are self perceived evaluation of symptom severity immediately before the dose (how the subject feels at that point in time). iTOSS (possible score of 0-9) is the sum of 3 individual participant-assessed symptom scores for eye itching/burning, eye tearing/watering, and eye redness each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Mean changes from baseline were calculated as treatment period iTOSS minus baseline iTOSS.
Time frame: Baseline to 14 days
Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS)
The rNCSS is a participant perceived evaluation of overall congestion symptom severity (evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe) which was completed once in the evening (PM), and once in the morning (AM). rNCSS is defined as the average of the PM rNCSS and the AM rNCSS of the next day prior to AM dosing. The mean change from baseline in rNCSS (daily, AM, PM)was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.
Time frame: Baseline to 14 days
End-of-treatment Assessment of Response to Therapy for Ocular Symptoms
Overall response to therapy assessment was done using a 7-point categorical scale in which participants rated their response to therapy as follows: +3 = Significantly Improved; +2 = Moderately Improved; +1 = Mildly Improved; 0 = No Change; -1= Mildly Worse; -2 = Moderately Worse; -3 = Significantly Worse.
Time frame: Day 14
Mean Change in Objective Assessment of Conjunctival Redness
Conjunctival redness was evaluated as a clinical sign of SAR by the investigator. Scoring of severity was rated according to a 4-point scale: 0 = normal; 1 = Slightly pink; 2 = Moderately pink, some dilation; 3 = Intense red vessels, dilated.
Time frame: Baseline to 14 days
Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. It measures five domains of functional impairment that are most important to subjects with SAR: practical problems, nasal symptoms, eye symptoms, activity limitations, and other symptoms. Participants scored their degree of impairment on a seven-point scale. (0 - 6). Mini RQLQ final score is the average of sub-scales, ranges from 0 (best possible outcome) to 6 (worst possible outcome).
Time frame: Baseline to 14 days
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. Activity limitations is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
Time frame: Baseline to 14 days
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. 'Practical Problems' is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
Time frame: Baseline to 14 days
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Nose Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
Time frame: Baseline to 14 days
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Eye Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
Time frame: Baseline to 14 days
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Other Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
Time frame: Baseline to 14 days
Participants were recruited at 6 clinical sites in the US.
| Milestone | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Started | 314 | 312 |
| Completed | 310 | 304 |
| Not completed | 4 | 8 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Other: could not attend appointment | 1 | 1 |
The Reflective Total Ocular Symptom Score (rTOSS) is the sum of 3 individual participant-assessed symptom scores (eye itching/burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. Subjects completed rTOSS in the evening (PM rTOSS; 12 hours post morning nasal spray use) and once in the morning (AM score: prior to nasal spray use). Daily (i.e. during one dosing interval) rTOSS is defined as the average of the PM rTOSS and the AM rTOSS of the next day prior to AM dosing. The mean change from baseline in (daily, AM, PM) TOSS was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS) | -0.91 ± 1.625 | -0.63 ± 1.525 |
rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For AM rToss, subjects completed rTOSS in the morning (AM score: prior to nasal spray use). The mean change from baseline in AM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in AM rTOSS | -0.96 ± 1.627 | -0.68 ± 1.573 |
rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For PM rTOSS, subjects completed rTOSS in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in PM rTOSS | -0.87 ± 1.735 | -0.60 ± 1.577 |
The AM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning | -0.35 ± 0.581 | -0.28 ± 0.553 |
The PM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning | -0.33 ± 0.626 | -0.24 ± 0.554 |
The AM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering | -0.35 ± 0.596 | -0.24 ± 0.589 |
The PM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering | -0.32 ± 0.653 | -0.19 ± 0.586 |
The AM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness | -0.26 ± 0.597 | -0.17 ± 0.613 |
The PM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness | -0.22 ± 0.628 | -0.17 ± 0.635 |
Instantaneous total ocular symptom scores (iTOSS) assessments are self perceived evaluation of symptom severity immediately before the dose (how the subject feels at that point in time). iTOSS (possible score of 0-9) is the sum of 3 individual participant-assessed symptom scores for eye itching/burning, eye tearing/watering, and eye redness each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Mean changes from baseline were calculated as treatment period iTOSS minus baseline iTOSS.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS) | -0.80 ± 1.443 | -0.55 ± 1.531 |
The rNCSS is a participant perceived evaluation of overall congestion symptom severity (evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe) which was completed once in the evening (PM), and once in the morning (AM). rNCSS is defined as the average of the PM rNCSS and the AM rNCSS of the next day prior to AM dosing. The mean change from baseline in rNCSS (daily, AM, PM)was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS) | -0.34 ± 0.547 | -0.20 ± 0.443 |
Overall response to therapy assessment was done using a 7-point categorical scale in which participants rated their response to therapy as follows: +3 = Significantly Improved; +2 = Moderately Improved; +1 = Mildly Improved; 0 = No Change; -1= Mildly Worse; -2 = Moderately Worse; -3 = Significantly Worse.
| Participants | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Significantly improved | 22 | 16 |
| Moderately Improved | 76 | 59 |
| Mildly Improved | 79 | 71 |
| No change | 81 | 97 |
| Mildly Worse | 21 | 20 |
| Moderatly Worse | 24 | 24 |
| Significantly Worse | 10 | 22 |
Conjunctival redness was evaluated as a clinical sign of SAR by the investigator. Scoring of severity was rated according to a 4-point scale: 0 = normal; 1 = Slightly pink; 2 = Moderately pink, some dilation; 3 = Intense red vessels, dilated.
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Change in Objective Assessment of Conjunctival Redness | -0.20 ± 0.815 | -0.15 ± 0.736 |
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. It measures five domains of functional impairment that are most important to subjects with SAR: practical problems, nasal symptoms, eye symptoms, activity limitations, and other symptoms. Participants scored their degree of impairment on a seven-point scale. (0 - 6). Mini RQLQ final score is the average of sub-scales, ranges from 0 (best possible outcome) to 6 (worst possible outcome).
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores | -0.98 ± 1.311 | -0.49 ± 1.091 |
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. Activity limitations is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities | -0.93 ± 1.384 | -0.39 ± 1.269 |
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. 'Practical Problems' is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems | -1.04 ± 1.476 | -0.57 ± 1.258 |
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Nose Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms | -1.09 ± 1.456 | -0.50 ± 1.257 |
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Eye Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms | -0.98 ± 1.512 | -0.55 ± 1.284 |
MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Other Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).
| Score on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms | -0.89 ± 1.607 | -0.48 ± 1.294 |
Collected over Participants were followed for the duration of study, an average of 3 weeks.. Non-serious events are listed at a 0.3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Propionate Nasal Spray | — | 0/314 (0%) | 8/314 (2.5%) |
| Placebo Nasal Spray | — | 0/312 (0%) | 8/312 (2.6%) |
| Event | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| PyrexiaGeneral disorders | 1/314 | 2/312 |
| BronchitisInfections and infestations | 0/314 | 2/312 |
| HeadacheNervous system disorders | 2/314 | 0/312 |
| PainGeneral disorders | 0/314 | 1/312 |
| InfluenzaInfections and infestations | 0/314 | 1/312 |
| MigraineNervous system disorders | 0/314 | 1/312 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/314 | 1/312 |
| Respiratory Tract CongestionRespiratory, thoracic and mediastinal disorders | 0/314 | 1/312 |
| HypersensitivityImmune system disorders | 0/314 | 1/312 |
| DermatitisSkin and subcutaneous tissue disorders | 0/314 | 1/312 |
| Age, Continuous(Years) | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray | Total |
|---|---|---|---|
| Mean | 40.4 ± 14.55 | 40.5 ± 16.36 | 40.5 ± 15.47 |
| Sex: Female, Male(Participants) | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray | Total |
|---|---|---|---|
| Female | 212 | 201 | 413 |
| Male | 102 | 111 | 213 |
The record gives a start of Dec 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Rhinitis, Allergic, Seasonal →